FDA clears regulatory pathway for Female Testosterone MDTS

Summary by 6ix AI

Acrux Limited has announced that the FDA has confirmed a clear regulatory pathway for its Female Testosterone metered-dose transdermal spray (MDTS) for postmenopausal women with hypoactive sexual desire disorder (HSDD). The FDA's feedback includes the requirement for two Phase III trials to demonstrate efficacy and safety, with flexibility in trial design. Acrux is also eligible to apply for a three-year exclusivity period upon submission, enhancing its commercial opportunity in the market. The announcement follows a recent FDA public workshop highlighting the need for female-specific testosterone treatments.

Written by 6ix AI from the company’s filing. How 6ix writes summaries